Infectious Disease · PANCE / PANRE

Pneumocystis jirovecii Pneumonia (PCP)

Opportunistic pneumonia caused by Pneumocystis jirovecii in HIV/AIDS and other immunocompromised hosts; presents with dyspnea, dry cough, and hypoxia.

Also known as: PCP, PJP, Pneumocystis pneumonia, Pneumocystis carinii pneumonia, Pneumocystis jirovecii

Overview

Opportunistic pulmonary infection caused by the fungus Pneumocystis jirovecii (formerly Pneumocystis carinii). Hallmark of advanced HIV/AIDS but also affects other immunocompromised patients including solid organ transplant recipients, patients on chronic corticosteroids, and those receiving immunosuppressive chemotherapy.

Epidemiology

Most cases in HIV-infected patients with CD4 <200 cells/microL. Incidence in HIV has declined dramatically with antiretroviral therapy and TMP-SMX prophylaxis. In non-HIV immunocompromised hosts (transplant, hematologic malignancy, vasculitis on steroids), PCP often presents more acutely and with higher mortality.

Try two board-style Pneumocystis jirovecii Pneumonia questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1Infectious DiseaseMedium
A 55-year-old male with newly diagnosed HIV (CD4 48, viral load 124,000, not on antiretroviral therapy) develops fever, dry cough, and progressive dyspnea over 3 weeks. CXR shows bilateral interstitial infiltrates. SpO2 90% on room air. Bronchoalveolar lavage with Gomori methenamine silver staining shows cysts and trophic forms of Pneumocystis jirovecii. LDH 680. PaO2 on room air 62 mmHg. Which of the following is the most appropriate treatment regimen?
  • ALiposomal amphotericin B plus flucytosine
  • BGanciclovir plus foscarnet sodium therapy
  • CCeftriaxone plus azithromycin combination
  • DTrimethoprim-sulfamethoxazole plus corticosteroids
Reveal answer & full explanation
Correct answer: D — Trimethoprim-sulfamethoxazole plus corticosteroids
  • ALiposomal amphotericin B plus flucytosine
  • BGanciclovir plus foscarnet sodium therapy
  • CCeftriaxone plus azithromycin combination
  • DTrimethoprim-sulfamethoxazole plus corticosteroids

Why Trimethoprim-sulfamethoxazole plus corticosteroids is correct

  • TMP-SMX 15-20 mg/kg/day (TMP component) in 3-4 divided doses for 21 days is first-line for Pneumocystis pneumonia (PCP)
  • This patient has moderate-severe disease (PaO2 below 70 mmHg on room air), so corticosteroids are mandatory, reducing mortality from 40% to 20%
  • Prednisone protocol: 40 mg BID x5 days, then 40 mg daily x5 days, then 20 mg daily x11 days
  • Corticosteroids blunt the vigorous inflammatory response triggered when organisms die during therapy

Why the others are wrong

  • Liposomal amphotericin B plus flucytosine — Treats cryptococcal and invasive fungal infection but has no activity against Pneumocystis jirovecii (right-concept-wrong-drug)
  • Ganciclovir plus foscarnet sodium therapy — Antivirals used for CMV, not appropriate for PCP (confused-with CMV)
  • Ceftriaxone plus azithromycin combination — Standard community-acquired pneumonia coverage with no activity against Pneumocystis (anchoring)

Additional high-yield points

  • Alternative PCP regimens: IV pentamidine; atovaquone plus dapsone; clindamycin plus primaquine
  • Antiretroviral therapy: start 2 weeks after PCP treatment initiation
  • Prophylaxis: TMP-SMX double-strength daily when CD4 below 200
Question 2Infectious DiseaseMedium
A 32-year-old male with HIV (CD4 count 35/mm3, not on antiretrovirals) presents with progressive shortness of breath, dry cough, and fever. Chest X-ray shows bilateral perihilar interstitial infiltrates. LDH is markedly elevated. Which of the following is the most likely opportunistic infection?
  • APneumocystis jirovecii pneumonia
  • BCytomegalovirus pneumonitis
  • CCryptococcal meningoencephalitis
  • DDisseminated Mycobacterium avium complex
Reveal answer & full explanation
Correct answer: A — Pneumocystis jirovecii pneumonia
  • APneumocystis jirovecii pneumonia
  • BCytomegalovirus pneumonitis
  • CCryptococcal meningoencephalitis
  • DDisseminated Mycobacterium avium complex

Why Pneumocystis jirovecii pneumonia is correct

  • Pneumocystis jirovecii pneumonia (PJP/PCP) is the most common AIDS-defining illness and typically strikes at CD4 <200/mm3 (here 35)
  • Classic presentation: subacute progressive dyspnea, dry (nonproductive) cough, and fever
  • Chest X-ray shows bilateral perihilar/interstitial ('bat-wing') infiltrates
  • Markedly elevated LDH (often >500) is a characteristic supportive clue
  • Diagnosis via induced sputum or bronchoalveolar lavage with silver stain, DFA, or PCR
  • Treatment: high-dose trimethoprim-sulfamethoxazole (TMP-SMX) for 21 days

Why the others are wrong

  • Cytomegalovirus pneumonitis — right-concept-wrong-setting; CMV in AIDS more often causes retinitis or colitis, and CMV pneumonitis is far more typical of transplant recipients than of untreated HIV.
  • Cryptococcal meningoencephalitis — confused-with the correct CD4 range; Cryptococcus at CD4 <100 presents as subacute meningitis (headache, fever, elevated opening pressure), not a diffuse interstitial pneumonia with high LDH.
  • Disseminated Mycobacterium avium complex — anchoring on the very low CD4 (<50); MAC causes fevers, night sweats, weight loss, cytopenias, and hepatosplenomegaly rather than an acute bilateral interstitial pneumonitis.

Additional high-yield points

  • Add adjunctive corticosteroids for PJP if PaO2 <70 mmHg or the alveolar-arterial (A-a) gradient >35
  • PJP prophylaxis when CD4 <200: TMP-SMX (also covers toxoplasmosis prophylaxis at CD4 <100)
  • MAC prophylaxis is indicated at CD4 <50 with azithromycin
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Pneumocystis jirovecii Pneumonia (PCP) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • HIV with CD4 <200 cells/microL — particularly <100
  • Chronic corticosteroid therapy (prednisone >=20 mg/day for >=4 weeks)
  • Solid organ or hematopoietic stem cell transplantation
  • Hematologic malignancy (especially ALL, CLL, lymphoma)
  • Immunosuppressive therapy: methotrexate, rituximab, calcineurin inhibitors, TNF-alpha inhibitors
  • Primary immunodeficiency (e.g., SCID, hyper-IgM)
  • Malnutrition in infants and severely debilitated adults

Pathophysiology

Pneumocystis is acquired through inhalation and persists in human lungs; clinical disease results from defective cell-mediated immunity. Organisms adhere to type I pneumocytes, causing diffuse alveolar damage, foamy intra-alveolar exudate, and surfactant abnormalities. Inflammation and impaired gas exchange produce hypoxia disproportionate to chest x-ray findings.

Clinical presentation

Symptoms

  • HIV-associated: subacute progressive dyspnea, dry nonproductive cough, low-grade fever, fatigue, weight loss over weeks
  • Non-HIV immunocompromised: more abrupt onset (days), higher fevers, more severe hypoxia
  • Pleuritic chest pain is uncommon
  • Hemoptysis is uncommon
  • Asymptomatic carriage occurs

Signs / physical exam

  • Tachypnea, tachycardia
  • Hypoxia disproportionate to chest auscultation findings
  • Lung exam often surprisingly clear or with diffuse fine crackles
  • Oral thrush is common in HIV-associated disease
  • Exertional desaturation on ambulation is sensitive in early disease

Classic findings

HIV patient with CD4 <200, subacute dry cough, hypoxia disproportionate to a chest x-ray showing bilateral perihilar interstitial or ground-glass infiltrates. Markedly elevated LDH and beta-D-glucan.

Differential diagnosis

  • Bacterial pneumonia — Lobar consolidation, productive cough, leukocytosis; responds to standard antibiotics
  • Viral pneumonia (influenza, COVID-19, RSV, CMV in transplant) — Bilateral infiltrates, similar imaging; viral PCR, CMV PCR
  • Tuberculosis — Upper-lobe cavitation, chronic cough, weight loss; AFB smear and culture
  • Pulmonary Kaposi sarcoma — HIV with violaceous cutaneous lesions, hemoptysis, characteristic flame-shaped infiltrates and pleural effusion
  • Drug-induced pneumonitis — Methotrexate, bleomycin, immune checkpoint inhibitors; temporal relationship and exclusion of infection
  • Pulmonary embolism — Sudden dyspnea, hypoxia; D-dimer, CTPA
  • Heart failure / pulmonary edema — Orthopnea, JVD, BNP elevation; responds to diuresis

Diagnostic workup

Diagnostic criteria

Definitive diagnosis: identification of Pneumocystis by direct fluorescent antibody, GMS, Giemsa, or PCR on respiratory specimen. Presumptive treatment may be initiated based on clinical and radiographic picture in classic settings while awaiting confirmation.

Labs

  • ABG (or pulse oximetry with ambulation) — degree of hypoxia drives adjunctive steroid use
  • LDH (often markedly elevated)
  • Beta-D-glucan (sensitive but not specific)
  • HIV testing and CD4 count if not known
  • Induced sputum with silver stain (GMS), DFA, or PCR for Pneumocystis
  • Bronchoalveolar lavage (BAL) with PCR or staining if induced sputum negative or non-diagnostic — gold standard sensitivity
  • CBC, BMP, LFTs prior to TMP-SMX (renal function, baseline LFTs)

Imaging

  • Chest x-ray: bilateral perihilar reticular or ground-glass infiltrates; may be normal early in disease
  • Chest CT (more sensitive): diffuse ground-glass opacities with relative subpleural sparing, occasional cysts and pneumothorax
  • Findings of upper-lobe disease with pneumatoceles and pneumothorax classically associated with aerosolized pentamidine prophylaxis

Diagnostic algorithm

flowchart TD
  A[Immunocompromised host<br/>HIV CD4 <200,<br/>steroids, transplant] --> B[Subacute dyspnea<br/>dry cough, hypoxia]
  B --> C[CXR / CT: bilateral<br/>ground-glass infiltrates]
  C --> D[LDH high, beta-D-glucan +]
  D --> E[Induced sputum / BAL<br/>GMS, DFA, PCR]
  E --> F[TMP-SMX x 21 days]
  F --> G{PaO2 <70 or<br/>A-a >=35?}
  G -->|Yes| H[Add prednisone taper<br/>40 BID x 5, 40 x 5, 20 x 11]
  G -->|No| I[TMP-SMX alone]
  F --> J[Secondary prophylaxis<br/>until CD4 >200 x 3 mo on ART]
PCP diagnostic and treatment pathway including adjunctive steroid indications.

Treatment

First-line

  • Trimethoprim-sulfamethoxazole (TMP-SMX) 15-20 mg/kg/day of TMP component IV or PO divided every 6-8 hours for 21 days — first-line for all severities
  • Adjunctive corticosteroids if PaO2 <70 mmHg on room air OR A-a gradient >=35 mmHg: prednisone 40 mg PO BID x 5 days, then 40 mg daily x 5 days, then 20 mg daily x 11 days (improves mortality in moderate to severe HIV-associated PCP)
  • Supportive care: supplemental oxygen, mechanical ventilation if needed
  • Initiate or continue antiretroviral therapy in HIV (no specific delay required for PCP, in contrast to cryptococcal meningitis)

Second-line / adjunct

  • Sulfa allergy or TMP-SMX intolerance — choose by severity:
  • Mild-moderate: dapsone-trimethoprim OR clindamycin-primaquine OR atovaquone
  • Severe: IV pentamidine 4 mg/kg/day or clindamycin-primaquine
  • G6PD testing prior to dapsone or primaquine (both cause hemolysis in G6PD deficiency)
  • Echinocandins (caspofungin) have weak activity and are NOT recommended as primary therapy
  • Secondary prophylaxis until CD4 >200 for >3 months on ART: TMP-SMX 1 single-strength or DS tablet daily; alternatives include dapsone, atovaquone, or aerosolized pentamidine

Complications

  • Respiratory failure requiring mechanical ventilation
  • Pneumothorax (especially with cystic disease)
  • Drug toxicity from TMP-SMX: rash, fever, neutropenia, hyperkalemia, AKI, hepatitis
  • Treatment failure and mortality higher in non-HIV immunocompromised hosts
  • Immune reconstitution inflammatory syndrome (IRIS) if ART started concurrently — usually mild

PANCE pearls

  • TMP-SMX is the unambiguous first-line treatment AND prophylaxis for PCP at all severities — sulfa allergy must be carefully verified.
  • Adjunctive corticosteroids are mortality-reducing when PaO2 <70 mmHg or A-a gradient >=35 mmHg in HIV-associated PCP — do not forget to add them.
  • LDH and beta-D-glucan are useful supportive labs but neither establishes nor excludes diagnosis.
  • Indications for primary PCP prophylaxis in HIV: CD4 <200 cells/microL, history of oropharyngeal candidiasis, or AIDS-defining illness.
  • Echinocandins (caspofungin) do not reliably treat PCP and should not be used as primary therapy.

References

  • AIDSinfo / NIH / HHS — Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV — Pneumocystis jirovecii pneumonia section
  • CDC — CDC — Pneumocystis pneumonia: epidemiology, diagnosis, and treatment
  • ATS / IDSA — Diagnosis and treatment of pneumonia in immunocompromised hosts (consensus statements)

Practice Infectious Disease questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.